Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPLETE: Senl_B19 CAR-T Bridging to Allo-HSCT in R/R B-ALL
NCT06581081Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2024
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Randomised, open-label trial of SENL-B19 in B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Event-Free Survival at 2 years. Started Oct 2024; status: recruiting.
02
Drugs
SENL-B19
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06581081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581081.